AUSTRALIAN biopharma giant CSL announced yesterday that it plans to expand its US presence over the next five years, with approximately US$1.5 billion (A$2.3 billion) in US capital investments.
These investments will generate hundreds of American jobs, strengthen US manufacturing capabilities of plasma-derived therapies, and aid in securing the US medicine supply chain, while helping to shore up an exemption to US President Donald Trump's proposed tariffs on imported pharmaceuticals (PD 29 Sep).
The company said in a news release that the plans reflect CSL's commitment to meet the growing clinical need for immunoglobulin over the long term.
"The US is the world's leading source for plasma, the main component of plasma derived therapies," said Paul McKenzie, CSL's Chief Executive Officer and Managing Director.
"These important medicines are often the most effective or only therapies available for many rare or serious diseases.
"By expanding our onshore production capacity in the US, we are deepening our commitment to patient care, creating high-quality jobs and driving innovation in the US."
The planned investments are subject to approval by CSL's Board of Directors.
Italian company Kedrion Biopharma has also pledged to invest million in the US, after its 10% intravenous immunoglobulin Qivigy received FDA approval in Sep.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Nov 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Nov 25
